(Q39588677)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

main subject

chronic myeloid leukemia

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Hyun-Gyung Goh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Min Lin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Takashi Fukushima

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Dongho Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Soo-Young Choi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Soo-Hyun Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Jeong Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Young-Seok Lee

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sang-Mi Oh

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Dong-Wook Kim

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

21 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

896-904

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.555569

10.3109/10428194.2011.555569

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21338281%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference